Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.
Mcap of top-10 most valued firms slumps Rs 4.95 lakh cr; TCS, Reliance hardest hit
The combined market valuation of all the top-10 most valued firms plunged Rs 4,95,061 crore last week, in line with a bearish trend in equities,
December 22, 2024